Background The dual goals of low-density lipoprotein-cholesterol (LDL-C) and C-reactive protein (CRP) reduction are important for secondary prevention of cardiovascular disease. However, the relevant factors of subclinical inflammation in patients with optimal LDL-C were not clearly demonstrated. This study sought to test the hypothesis that the metabolic syndrome (MetS) is associated with subclinical inflammation in patients achieving optimal LDL-C. Methods and Results A total of 227 Japanese subjects with a prior history of ischemic heart disease and optimal LDL-C (LDL-C <100 mg/dl) were enrolled. When compared with patients with low CRP (<0.1 mg/dl), those with a high CRP (≥0.1 mg/dl) had a significantly higher prevalence of visceral obesity, elevated triglyceride, lower high-density lipoprotein-cholesterol (HDL-C), hypertension, impaired fasting glucose, and a higher prevalence of MetS. A linear relationship between an increase in number of MetS components and CRP was observed (trend, p<0.001). In multivariate logistic analysis, visceral obesity (odds ratio 6.54; 95% confidence interval 2.99-14.3), low HDL-C (2.78; 1.09-7.12) and impaired fasting glucose (6.72; 3.30-13.7), and MetS (10.4; 5.18-20.7) were associated with higher CRP. Conclusions MetS is well associated with higher CRP concentrations in patients who achieved optimal LDL-C levels. (Circ J 2008; 72: 2046 -2050 
rterial inflammation plays a central role in the initiation and progression of atherosclerosis. C-reactive protein (CRP) has been shown to predict future cardiovascular events. 1 The existence of a chronic inflammatory state in spite of the treatment with statin therapy after coronary intervention has been suggested and associated with adverse cardiovascular events. 2, 3 Although the dual goals of low-density lipoprotein-cholesterol (LDL-C) and CRP reduction have been considered a clinical therapeutic target among high-risk patients with a prior history of cardiovascular events for the strategy of secondary prevention, the number of patients who achieve and maintain lower concentration of CRP might be suboptimal, despite the established efficacy of statins in lowering LDL-C level.
However, the relevant factors of chronic subclinical inflammation in patients who attained optimal LDL-C levels were not clearly demonstrated. Thus, we designed a crosssectional study to test the hypothesis that the metabolic syndrome (MetS) is associated with subclinical inflammation in patients whose LDL-C levels are optimal.
Methods

Subjects
Between August and November 2007, we screened 376 consecutive outpatients who attended our medical center with a prior history of cardiovascular disease (CVD) and coronary intervention. A total of 227 patients were enrolled whose LDL-C levels were optimal for secondary prevention (LDL-C <100 mg/dl). All patients were Japanese and living in Tanabe City and Nishimuro District, located in the southern part of Wakayama Prefecture in Japan. Patients were ineligible for the study if they had a coexisting chronic inflammatory disease and a malignant disease, suffered from acute myocardial infarction, had undergone percutaneous coronary intervention or coronary-artery bypass surgery within the previous 6 months, or had a creatinine level of more than 2.0 mg/dl.
Definitions
Diagnosis of MetS was based on the criteria proposed by the Japanese committee for the Diagnosis Criteria of Metabolic Syndrome in April 2005. 4 Those with an increased waist circumference (≥85 cm for men and ≥90 cm for women) and more than 2 of the following components were considered as having MetS: (1) raised triglyceride (TG) defined as TG ≥150mg/dl and/or reduced highdensity lipoprotein-cholesterol (HDL-C) defined as HDL-C <40 mg/dl or under treatment for this type of dyslipidemia; (2) elevated blood pressure defined as blood pressure ≥130 and/or diastolic blood pressure ≥85, or taking medication A smoking habit and alcohol drinking was grouped into "yes" or "no". Physical activity information (International Physical Activity Questionnaire, short last 7-day format) was collected using a standardized questionnaire, and classified as low, moderate, or high according to the questionnaire scoring protocol. 5 
Laboratory Measurements
Venous blood samples were drawn from each subject after overnight fasting. Total cholesterol, HDL-C, LDL-C, TG, glucose, and creatinine were measured enzymatically on a Hitachi 7600 autoanalyzer. CRP was measured by a latex particle-enhanced turbidimetric immunoassay using a N-assay LA CRP-S D-type kit (Nitttobo Medical, Tokyo, Japan) on the autoanalyzer, and the values lower than the measurement limit (0.02 mg/dl) were considered to be 0.02 mg/dl. The inter-assay coefficients of variation for CRP levels were 1.9%, 1.2%, and 0.73% at 0.13, 0.33, and 0.55 mg/dl, respectively, while the intra-assay coefficients of variation were 2.1%, 1.3%, and 1.0% at 0.12, 0.21, and 0.53 mg/dl, respectively. The CRP concentrations were proposed to be <0.10 mg/dl as low risk, 0.10-0.30 mg/dl as intermediate risk, and >0.30 mg/dl as high risk for coronary heart disease in Western countries. 6 In this study, we defined CRP <0.10 mg/dl as a low CRP level and CRP ≥0.10 mg/dl as a high CRP level because of substantially lower CRP values in Japan compared to those in Western countries. 7, 8 
Statistical Analysis
All continuous variables were shown as mean ± SD, except for CRP [shown as medians (25 th and 75 th percentile)], whereas categorized data were expressed as percentages. For continuous variables, values were compared using 2-sample t-tests for independent samples. Differences in proportion were compared with a chi-square test or Fisher's exact test, as appropriate.
To evaluate for the distribution of CRP levels and the association between CRP levels and the number of MetS, we classified all study subjects as having 0, 1, 2, 3, or 4 components of MetS and assessed for evidence of a relationship with median CRP levels across these groups using the Kruskal -Wallis test. Models were extended to the subset of patients who were treated with statins and without statins separately because the pathophysiological mechanisms on CRP levels might be different between these groups.
Thereafter, we calculated the crude; age-, sex-adjusted, and multivariate-adjusted odds ratios of high CRP levels (≥0.1 mg/dl) by using logistic regression models with each component of MetS as an exposure of interest. The crude and adjusted odds ratios of high CRP were also determined by clustering the components of MetS. In these analysis, the odds ratios of high CRP were calculated by comparing subjects with 2, 3, and 4 components of MetS with those with 0 or 1 component of MetS because only 29 subjects with no component of MetS were prevalent. Finally, the crude and adjusted odds ratios of high CRP were calculated by comparing subjects with MetS (increased waist circumference and ≥2 components) and without MetS. In the multivariate models, age, sex, LDL-C levels, smoking habits, physical activity, use of aspirin, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, statin drugs, estimated glomerular filtration rate (GFR) (Modification of Diet in Renal Disease Method 9 ) were adjusted. Chicago, IL, USA). A 2-sided value of p≤0.05 was regarded as statistically significant.
Results
The study population comprised of 227 subjects (180 men and 47 women) with a mean age of 71.8±10.2 years. The clinical characteristics of the study subjects are presented in Table 1 . Approximately half of subjects (50.7%) had visceral obesity and 79 (34.8%) had MetS. The majority of subjects (90.7%) had taken aspirin and 59.5% had statins. The median CRP level was 0.08 mg/dl. No patients had taken thiazolidinediones or had received hormone replacement therapy. The prevalence of positive criteria for all components of MetS was higher in patients with a high CRP than those with a low CRP ( Table 2) .
A linear relationship between an increase in the number of MetS components and CRP concentrations was observed ( Fig 1A) ; median CRP levels for those with 0, 1, 2, 3, and 4 characteristics of MetS were 0.05, 0.05, 0.07, 0.15, and 0.19 mg/dl, respectively (trend, p<0.001). Similar results were obtained when subjects were classified according to 1.00 Statin use Overall the use of statins. Figs 1B,C shows the relationship between the number of MetS components and CRP in the subjects with and without statin use, respectively. Median CRP levels were 0.05, 0.06, 0.07, 0.14, and 0.18 mg/dl in those with statin use (trend, p<0.001), and 0.05, 0.05, 0.07, 0.21, and 0.20 mg/dl in those without statin use (trend, p<0.001). Table 3 shows the crude and multivariate-adjusted odds ratios of high CRP levels associated with individual or several components of MetS. In the multivariate models, visceral obesity (p<0.001), low HDL-C (p=0.033), and impaired fasting glucose (p<0.001) were significantly associated with an increased odds ratio of high CRP levels. The multivariate-adjusted odds ratio of high CRP was 0.90 (95% confidence interval (CI), 0.44-1.86, p=0.781), 1.00 (95% CI, 0.98-1.03, p=0.301), and 0.98 (95% CI, 0.96-1.00, p=0.030) for statin use, LDL-C levels, and estimated GFR, respectively. Subjects with 3 and 4 components of MetS had an increased odds ratio of 16.9 and 36.8 for high CRP, compared with that of those with a 0 or 1 component. Patients with MetS had a 10.4-fold increased odds of having high CRP levels compared with counterparts without the MetS.
Discussion
In our cross-sectional study, we found that subjects with higher CRP levels were likely to have each component of MetS (visceral obesity, elevated TG, low HDL-C levels, hypertension, and impaired fasting glucose) and had a higher prevalence of MetS compared with those with lower CRP levels. We also found that CRP concentrations were associated with the number of MetS in Japanese subjects, confirming previous findings, 10, 11 and extending them to patients in which LDL-C had attained optimal levels.
Abundant evidence has accumulated to demonstrate that CRP is associated with MetS 12,13 and predicts diabetes and CVD events independently of traditional risk factors. 14, 15 Abdominal adipose tissue is a major source of cytokines, including Interleukin-6, which is an important determinant of hepatic CRP synthesis. 16 It remains uncertain whether impacts of statin treatment on inflammatory markers are different between patients with and without MetS. Nicholls et al demonstrated that patients with a higher body mass index had a greater proportionate decrease in CRP compared with those with a lower BMI who had received intensive statin therapy. 17 It is unclear whether statin treatment has a different magnitude of effect on the LDL-C and CRP levels between patients with and without MetS in our study, because we did not assess their baseline levels and serial changes during statin therapy. We speculate that baseline CRP levels in metabolic patients before statin treatment are too high to reach the lower goals of CRP <0.10 mg/dl despite having achieved optimal LDL-C levels after statin treatment.
A previous study demonstrated that patients who had CRP levels of more than 0.2 mg/dl (2 mg/L) after statin therapy had higher event rates than those who had lower CRP levels at all levels of LDL-C. 18 Statins should be considered as the first choice for those patients who have higher levels of both LDL-C and CRP. To the best of our knowledge, however, little is known about the treatment for patients with optimal LDL-C levels and higher CRP concentrations despite whether they had already received statin therapy. We found that MetS is highly prevalent and is a powerful contributor towards high serum CRP concentrations in patients with previous coronary heart disease whose LDL-C levels are optimal. In the light of the results of this study, aggressive treatment of the components of MetS should be considered in order to decrease CRP levels and reduce the future cardiovascular events. The pharmacological treatments for coronary artery disease (statins, angiotensin-converting enzyme inhibitors, and -blockers) have little effect on the modification of the central components of MetS. Therefore, other approaches such as lifestyle modification might be crucial to target a critical factor in the etiology of the prevalent form of MetS. Further prospective studies are needed to understand the key mechanisms of MetS that are responsible for the chronic inflammatory states.
In conclusion, MetS is well associated with high CRP levels in patients who achieved optimal LDL-C levels. This study would have great implications for the management of chronic inflammatory conditions and atherosclerotic disease as a second CVD prevention.
Study Limitations
Some limitations of this study must be considered. First, this is a single center study and the number of the study population was relatively small. It is possible that the results depended on the study cohort and patients' baseline characteristics. Second, the present cross-sectional study does not allow for inferring causality from the results, which should be a considered hypothesis, generating and requiring confirmation by prospective studies. Third, several crucial plasma metabolic markers (eg, serum insulin concentration, adiponectin, tumor necrotic factor-, interleukin-6) were not measured in this study. It was not possible to investigate the potential mechanisms responsible for the significant and independent association between MetS and a higher level of CRP. Fourth, although a few studies demonstrated the impact of MetS on the long-term outcome among patients with coronary artery disease, [19] [20] [21] the role of treatment for MetS for secondary prevention of CVD is inadequately defined. Fifth, urinary albumin was not assessed in this study, although a previous study showed a relationship between albuminuria and CRP and MetS, 22 and towards possible future cardiovascular event risks. 23 Finally, the present study results were only obtained from Japanese patients, which could not be simply extrapolated to other ethnic groups.
